Search details
1.
Dysregulation of intracellular redox homeostasis by the SARS-CoV-2 ORF6 protein.
Virol J
; 20(1): 239, 2023 10 18.
Article
in English
| MEDLINE | ID: mdl-37853388
2.
Infectious Toscana Virus in Seminal Fluid of Young Man Returning from Elba Island, Italy.
Emerg Infect Dis
; 28(4): 865-869, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35318936
3.
Toscana virus non-structural protein NSs acts as E3 ubiquitin ligase promoting RIG-I degradation.
PLoS Pathog
; 15(12): e1008186, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31815967
4.
Antibody response to SARS-CoV-2 in infected patients with different clinical outcome.
J Med Virol
; 93(4): 2548-2552, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33427302
5.
Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience.
BMC Infect Dis
; 21(1): 630, 2021 Jul 01.
Article
in English
| MEDLINE | ID: mdl-34210259
6.
SARS-CoV-2 Antibody Response in Persons with Past Natural Infection.
N Engl J Med
; 385(1): 90-92, 2021 07 01.
Article
in English
| MEDLINE | ID: mdl-33852796
7.
SARS-CoV-2 omicron sub-lineages differentially modulate interferon response in human lung epithelial cells.
Virus Res
; 332: 199134, 2023 07 15.
Article
in English
| MEDLINE | ID: mdl-37192725
8.
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID.
Viruses
; 15(3)2023 02 23.
Article
in English
| MEDLINE | ID: mdl-36992322
9.
Nucleopore Traffic Is Hindered by SARS-CoV-2 ORF6 Protein to Efficiently Suppress IFN-ß and IL-6 Secretion.
Viruses
; 14(6)2022 06 11.
Article
in English
| MEDLINE | ID: mdl-35746745
10.
Human Polymorphonuclear Cells Support Zika Virus to Cross Endothelial Monolayer and Access Bloodstream.
Pathogens
; 11(3)2022 Mar 05.
Article
in English
| MEDLINE | ID: mdl-35335645
11.
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine.
Vaccines (Basel)
; 10(2)2022 Jan 22.
Article
in English
| MEDLINE | ID: mdl-35214630
12.
Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees.
Vaccines (Basel)
; 10(5)2022 May 19.
Article
in English
| MEDLINE | ID: mdl-35632563
13.
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines.
Eur J Cancer
; 171: 143-149, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35717822
14.
Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine.
Vaccines (Basel)
; 10(9)2022 Sep 10.
Article
in English
| MEDLINE | ID: mdl-36146590
15.
SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity.
Viruses
; 13(8)2021 07 23.
Article
in English
| MEDLINE | ID: mdl-34452305
16.
Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants.
Vaccines (Basel)
; 9(5)2021 May 18.
Article
in English
| MEDLINE | ID: mdl-34069852
17.
Efficient Inactivation of SARS-CoV-2 and Other RNA or DNA Viruses with Blue LED Light.
Pathogens
; 10(12)2021 Dec 08.
Article
in English
| MEDLINE | ID: mdl-34959545
18.
How long can SARS-CoV-2 persist in human corpses?
Int J Infect Dis
; 106: 1-2, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33746091
19.
Comparative Performance of a New SARS-CoV-2 Rapid Detection System.
Microbiol Spectr
; 9(2): e0020521, 2021 10 31.
Article
in English
| MEDLINE | ID: mdl-34643409
20.
Identification of a Neutralizing Epitope on TOSV Gn Glycoprotein.
Vaccines (Basel)
; 9(8)2021 Aug 19.
Article
in English
| MEDLINE | ID: mdl-34452049